Reply to: Comment on 'Androgenetic Alopecia Present in the Majority of Patients Hospitalized with COVID-19'
August 2020
in “
Journal of The American Academy of Dermatology
”
Studysummary This letter discusses existing research and encourages further studies on the relationship between androgenetic alopecia and COVID-19 severity, reporting no new clinical results.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This document is a reply to a comment on a previous study that found a high incidence of androgenetic alopecia (AGA) in COVID-19 patients. The author clarifies that the previous study was not a comparative study and did not establish a correlation between AGA and COVID-19 severity. However, the study did find that full AGA men had an increased risk of testing positive for COVID-19 and that the Gabrin sign (Hamilton-Norwood scale) was associated with worse outcomes in men. The author suggests that future studies should control for gender and specific anti-androgen use to refine COVID-19 data. The document includes a table comparing the proportions of men with AGA in the Madrid COVID-19 study with a previous study.
